About Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
Martin-Luther-Universität Halle-Wittenberg
2
University of Ulm
2
Aktion Bronchialkarzinom e.V.
1
NSABP Foundation Inc
1
Technical University of Munich
1
Clinical Trials at Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
During the past decade, Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on
average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Trial of Docetaxel, Oxaliplatin and Capecitabine (TEX) in Advanced or Metastatic Gastric Cancer
2007-08-01
2013-01-01
Completed
56
Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab
2007-11-01
2012-05-01
Completed
224
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
2008-04-01
2014-07-01
Terminated
3,509
A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
2010-01-26
2017-08-07
Completed
452
Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer
2011-05-01
2018-08-15
Completed
250
Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
2012-05-01
Completed
544
A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)
2012-12-03
2017-05-31
Terminated
182
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Martin-Luther-Universität Halle-Wittenberg" with 2 trials
sponsored, "University of Ulm" with 2 trials sponsored, "Aktion Bronchialkarzinom e.V." with 1 trials sponsored and "NSABP Foundation Inc"
with 1 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH"
#1 collaborator was "Roche Pharma AG" with 2 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Hoffmann-La Roche" with 1 trials as a collaborator and "National Center for Tumor Diseases, Heidelberg" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were
collaborators in the rest 7 trials.
Clinical Trials Conditions at Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
According to Clinical.Site data, the most researched conditions in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH" are
"Breast Cancer" (3 trials), "Acute Myeloid Leukemia" (2 trials), "Acute Lymphoblastic Leukemia" (1 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Colorectal Cancer" (1 trials). Many other conditions were trialed in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH" in a lesser frequency.
Clinical Trials Intervention Types at Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
Most popular intervention types in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH" are "Drug" (10 trials). Other intervention types were less common.
The name of intervention was led by "Bevacizumab" (3 trials), "Trastuzumab" (3 trials), "Capecitabine" (2 trials), "Pertuzumab" (2 trials) and "5-FU/LV" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
The vast majority of trials in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH" are
8 trials for "All" genders and 2 trials for "Female" genders.
Clinical Trials Status at Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH
Currently, there are NaN active trials in "Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 7 completed trials in Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Klinik Fulda, Medizinisches Versorgungszentrum Osthessen GmbH, 1 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".